^
    Back
    Association details:
    Biomarker:MTOR M2327I
    Cancer:Breast Cancer
    Drug:RapaLink-1 (mTOR inhibitor, mTORC1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Nature
    Title:

    Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor

    Excerpt:
    RapaLink-1 at low doses (3–10 nM) was the only drug regimen capable of inhibiting mTOR signaling in both F2108L mTOR and M2327I mTOR expressing cells (Figures 4a, b).
    DOI:
    10.1038/nature17963